You are here

Vir Biotechnology

HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins

HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins

Xtalks

Vir Biotechnology

clinical trials

Flag link:

Vir antibody drug aimed at influenza A fails in clinical trial

Vir antibody drug aimed at influenza A fails in clinical trial

Stat

Vir Biotechnology

clinical trials

Flag link:

Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine

Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine

Biopharma Reporter

Vir Biotechnology

Gates Foundation

Flag link:

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners

Fierce Biotech

Vir Biotechnology

Flag link:

In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb

In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb

Endpoints

Vir Biotechnology

federal contracts

Flag link:

Vir doses first subject in Phase II hepatitis D virus treatment trial

Vir doses first subject in Phase II hepatitis D virus treatment trial

Clinical Trials Arena

Vir Biotechnology

clinical trials

Flag link:

FDA halts Vir, GSK antibody use in response to COVID subvariant's spread

FDA halts Vir, GSK antibody use in response to COVID subvariant's spread

BioPharma Dive

Vir Biotechnology

Flag link:

FDA cuts off use of GSK's Covid treatment in almost half of the US as BA.2 spreads

FDA cuts off use of GSK's Covid treatment in almost half of the US as BA.2 spreads

Endpoints

Vir Biotechnology

monoclonal antibodies

Flag link:

Officials limit an antibody therapy, saying it’s ineffective against BA.2 variant of Omicron

Officials limit an antibody therapy, saying it’s ineffective against BA.2 variant of Omicron

Stat

Vir Biotechnology

monoclonal antibodies

Flag link:

Big Pharma has skirted long Covid, but a pipeline of small biotechs are testing treatments for lingering symptoms

Big Pharma has skirted long Covid, but a pipeline of small biotechs are testing treatments for lingering symptoms

Endpoints

Vir Biotechnology

Atea Pharmaceuticals

Flag link:

With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda

With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda

Endpoints

Vir Biotechnology

Johanna Friedl-Naderer

Flag link:

GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand

GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demand

Fierce Pharma

Vir Biotechnology

drug manufacturing

Samsung BioLogics

Flag link:

Vir expands partnership with Gates Foundation, adding $50M for HIV and malaria antibody research initiative

Vir expands partnership with Gates Foundation, adding $50M for HIV and malaria antibody research initiative

Endpoints

Vir Biotechnology

Gates Foundation

Flag link:

US pauses distribution of GSK/Vir's Covid mAb not due to Omicron, but greater supply of Eli Lilly mAbs

US pauses distribution of GSK/Vir's Covid mAb not due to Omicron, but greater supply of Eli Lilly mAbs

Endpoints

Vir Biotechnology

monoclonal antibodies

Flag link:

New data shows GSK-Vir drug works against all Omicron mutations

New data shows GSK-Vir drug works against all Omicron mutations

Reuters

Vir Biotechnology

Omicron COVID-19 variant

Flag link:

MHRA okays GSK’s Xevudy as data suggest it works against Omicron

MHRA okays GSK’s Xevudy as data suggest it works against Omicron

Pharmaforum

Vir Biotechnology

Omicron COVID-19 variant

Flag link:

GlaxoSmithKline, Vir target emergency authorization for intramuscular COVID-19 antibody drug with new trial win

GlaxoSmithKline, Vir target emergency authorization for intramuscular COVID-19 antibody drug with new trial win

Fierce Pharma

Vir Biotechnology

Flag link:

GSK and Vir turn to US for distribution as Covid-19 mAb treatment nears blockbuster status

GSK and Vir turn to US for distribution as Covid-19 mAb treatment nears blockbuster status

Endpoints

Vir Biotechnology

monoclonal antibodies

Flag link:

The sellside’s most controversial products

The sellside’s most controversial products

EP Vantage

Vir Biotechnology

Flag link:

GSK, Vir build case for COVID-19 antibody drug with new study data

GSK, Vir build case for COVID-19 antibody drug with new study data

BioPharma Dive

Vir Biotechnology

clinical trials

Flag link:

Pages